Serum CYFRA 21-1 is one of the most reliable tumor markers for breast carcinoma

Cancer

Volumn 89, Issue 6, 2000, Pages 1285-1290

  Nakata, Bunzo ^a   Ogawa, Yoshinari ^a   Ishikawa, Tetsuro ^a   Ikeda, Katsumi ^a   Kato, Yasuyuki ^a   Nishino, Hiroji ^a   Hirakawa, Kosei ^a  

^a OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Breast carcinoma; CA 15 3; Carcinoembryonic antigen (CEA); CYFRA 21 1; Disease free survival; Prognosis

Indexed keywords

CA 15-3 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CYTOKERATIN 19 FRAGMENT; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; TUMOR MARKER;

ADULT; AGED; ARTICLE; BREAST CARCINOMA; CANCER SURVIVAL; CONTROLLED STUDY; ENZYME IMMUNOASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS;

ANTIGENS, NEOPLASM; BREAST DISEASES; BREAST NEOPLASMS; CA-15-3 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; FEMALE; HUMANS; KERATINS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 0034666090     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/1097-0142(20000915)89:6<1285::AID-CNCR13>3.0.CO;2-G     Document Type: Article

References (22)

1. Determination of the specificities of monoclonal antibodies recognizing members of the CEA family using a panel of transfectants
2. Monoclonal antibodies against human milk-fat globule membranes detecting differentiation antigens of the mammary gland and its tumors
3. Differential reactivity of a novel monoclonal antibody (DF3) with human malignant versus benign breast tumors
4. Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer
5. The catalog of human cytokeratins: Patterns of expression in normal epithelia, tumors and cultured cells
6. Cytokeratin expression in breast cancer: Phenotypic changes associated with disease progression
7. Immunohistochemical detection of breast specific antigens and cytokeratins in metastatic breast carcinoma in the liver
8. Quantitative polymerase chain reaction for the detection of micrometastases in patients with breast cancer
9. Serum fragments of cytokeratin subunit 19 measured by CYFRA 21-1 immunoradiometric assay as a marker of lung cancer
10. Breast tumours
11. Measurement of cytokeratin 19 fragments as a marker of lung cancer by CYFRA 21-1 enzyme immunoassay
12. Clinical usefulness of CYFPA assay in diagnosing lung cancer: Measurement of serum cytokeratin fragment
13. Immunocytochemical distribution of a breast carcinoma associated glycoprotein identified by monoclonal antibodies
14. c-erbB-2 oncoprotein, CEA, and CA 15.3 in patients with breast cancer: Prognostic value
15. Human tissue polypeptide antigen in breast cancer
16. A new tumor marker MCA in breast cancer diagnosis
17. Serum levels and biochemical characteristics of cancer-associated antigen GA-549, a circulating breast cancer marker
18. Prostate-specific antigen is a new favorable prognostic indicator for women with breast cancer
19. Clinical significance of serum CYFRA 21-1 in gastric cancer
20. The contribution of ultrasonography to the differential diagnosis of breast cancer
21. Study of a new tumor marker, CYFRA 21-1, in malignant and nonmalignant diseases
22. CYFRA 21-1: A new marker in lung cancer